Phase I, Phase I
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Volunteers
Health Professionals
What is the purpose of this trial?
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Adriana Kahn, MD
- Andrea Brennan, PA
- Caitlin Gallagher, APRN
- Carrie Fijal, MSN, AGPCNP-BC, OCN, APRN
- Clarice Grens, APRN
- Elizabeth Gaa, APRN
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jill Lacy, MD
- Joseph Kim, MD
- Julia Marie DiBartolomeo, APRN
- Kirsten Dooley, APRN
- Mandy DeMerchant, APRN
- Megan Shulman, APRN
- Michael Cecchini, MD
- Pamela L. Kunz, MD
- Patricia LoRusso, DO
- Raghav Sundar, MD, PhD
- Sara Anastasio, APRN, RN
- So Yeon Kim, MD
- Teresa White, APRN
- Thejal Srikumar, MD, MPH
- Virginia Syombathy, APRN
- Xiao Wang, MD
- Last Updated04/29/2026
- Study IRB#2000036028